NCT07110246

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2025-11-07Est. Completion: 2032-03-31

Enrollment target: 96 participants

Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States
University of California, San Francisco, San Francisco, California, United States
Children's National Hospital, Washington D.C., District of Columbia, United States
University of Florida, Gainesville, Florida, United States
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States
John Hopkins Medical Center, Baltimore, Maryland, United States
St. Louis Children's Hospital Washington University in St. Louis, St Louis, Missouri, United States
Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, New Jersey, United States
Duke University Medical Center, Durham, North Carolina, United States
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
University of Utah, Salt Lake City, Utah, United States

Other microbiome trials you might be interested in

A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)Recruiting

Non-Small Cell Lung Cancer

Multicenter prospective assessment of MET concordance and tumor gene profiling in treatment-naïve NSCLC

Anyang, ChinaEst. completion Mar 31, 2027

View Trial →

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Phase 2Recruiting

Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder CarcinomaBreast CarcinomaCervical CarcinomaColon CarcinomaColorectal CarcinomaEndometrial CarcinomaEsophageal Carcinoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.